Association of Daily Step Patterns With Mortality in US Adults

1週間の歩行パターンと死亡リスクの関連を明らかに --週2回しっかり歩くことで健康は維持できるか？--. 京都大学プレスリリース. 2023-03-30.[Importance] Previous studies have shown that individuals who regularly walk, particularly 8000 daily steps or more, experience lower mortality. However, little is known about the health benefits of walking intensively only a few days a week. [Objective] To evaluate the dose-response association between the number of days an individual takes 8000 steps or more and mortality among US adults. [Design, Setting, and Participants] This cohort study evaluated a representative sample of participants aged 20 years or older in the National Health and Nutrition Examination Surveys 2005-2006 who wore an accelerometer for 1 week and their mortality data through December 31, 2019. Data were analyzed from April 1, 2022, to January 31, 2023. [Exposures] Participants were grouped by the number of days per week they took 8000 steps or more (0 days, 1-2 days, and 3-7 days). [Main Outcomes and Measures] Multivariable ordinary least squares regression models were used to estimate adjusted risk differences (aRDs) for all-cause and cardiovascular mortality during the 10-year follow-up, adjusting for potential confounders (eg, age, sex, race and ethnicity, insurance status, marital status, smoking, comorbidities, and average daily step counts). [Results] Among 3101 participants (mean [SD] age, 50.5 [18.4] years; 1583 [51.0%] women and 1518 [49.0%] men; 666 [21.5%] Black, 734 [23.7%] Hispanic, 1579 [50.9%] White, and 122 [3.9%] other race and ethnicity), 632 (20.4%) did not take 8000 steps or more any day of the week, 532 (17.2%) took 8000 steps or more 1 to 2 days per week, and 1937 (62.5%) took 8000 steps or more 3 to 7 days per week. Over the 10-year follow-up, all-cause and cardiovascular deaths occurred in 439 (14.2%) and 148 (5.3%) participants, respectively. Compared with participants who walked 8000 steps or more 0 days per week, all-cause mortality risk was lower among those who took 8000 steps or more 1 to 2 days per week (aRD, −14.9%; 95% CI −18.8% to −10.9%) and 3 to 7 days per week (aRD, −16.5%; 95% CI, −20.4% to −12.5%). The dose-response association for both all-cause and cardiovascular mortality risk was curvilinear; the protective association plateaued at 3 days per week. Different thresholds for the number of daily steps between 6000 and 10 000 yielded similar results. [Conclusions and Relevance] In this cohort study of US adults, the number of days per week taking 8000 steps or more was associated with a lower risk of all-cause and cardiovascular mortality in a curvilinear fashion. These findings suggest that individuals may receive substantial health benefits by walking just a couple days a week

Helicobacter pylori infection is associated with an increased rate of diabetes.

ObjectiveChronic infections could be contributing to the socioeconomic gradient in chronic diseases. Although chronic infections have been associated with increased levels of inflammatory cytokines and cardiovascular disease, there is limited evidence on how infections affect risk of diabetes.Research design and methodsWe examined the association between serological evidence of chronic viral and bacterial infections and incident diabetes in a prospective cohort of Latino elderly. We analyzed data on 782 individuals aged >60 years and diabetes-free in 1998-1999, whose blood was tested for antibodies to herpes simplex virus 1, varicella virus, cytomegalovirus, Helicobacter pylori, and Toxoplasma gondii and who were followed until June 2008. We used Cox proportional hazards regression to estimate the relative incidence rate of diabetes by serostatus, with adjustment for age, sex, education, cardiovascular disease, smoking, and cholesterol levels.ResultsIndividuals seropositive for herpes simplex virus 1, varicella virus, cytomegalovirus, and T. gondii did not show an increased rate of diabetes, whereas those who were seropositive for H. pylori at enrollment were 2.7 times more likely at any given time to develop diabetes than seronegative individuals (hazard ratio 2.69 [95% CI 1.10-6.60]). Controlling for insulin resistance, C-reactive protein and interleukin-6 did not attenuate the effect of H. pylori infection.ConclusionsWe demonstrated for the first time that H. pylori infection leads to an increased rate of incident diabetes in a prospective cohort study. Our findings implicate a potential role for antibiotic and gastrointestinal treatment in preventing diabetes

Apolipoprotein E Genotype and Cardiovascular Diseases in the Elderly

The apolipoprotein E (APOE) genotype is a genetic risk factor for dementia, Alzheimer’s disease, and cardiovascular disease (CVD). It includes three alleles (e2, e3, e4) that are located on chromosome 19q3.2. The e3 allele is the most common and is more common in people of Northern European ancestry and less common in those of Asian ancestry. Those with at least one e4 allele are at increased risk for CVD outcomes. It is well established that the presence of an e4 allele is linked to higher low-density lipoprotein cholesterol levels, even at young ages. Even though most CVD occurs in older people, there are few studies of the effects of APOE on CVD in older people. This review addresses recent research on the links between APOE, CVD, and vascular mechanisms by which APOE may affect CVD in the elderly

Type 2 Diabetes, Risk of Dementia and Cognitive Decline, and the Competing Risk of Mortality Among Middle-Aged and Older Adults

Type 2 diabetes is highly prevalent and has been linked with an increased risk of dementia and premature mortality. Earlier death among people with diabetes may impact the association between diabetes and dementia. This is particularly important for populations with a high burden of diabetes, including Mexican Americans and African Americans. The objective of this dissertation was to evaluate the association of diabetes with incidence of dementia and cognitive impairment without dementia (CIND) and cognitive decline in late-life among Mexican Americans and in mid-life among African Americans and whites while accounting for the competing risk of mortality. The study populations included: 1) a cohort of dementia-free older Mexican Americans (n=1617) aged 60-98 from the Sacramento Area Latino Study on Aging (SALSA) followed for 10 years beginning in 1998 and 2) a cohort of middle-aged African Americans and whites (n=1886) aged 48-70 from the Atherosclerosis Risk in Communities (ARIC) Study followed for 14 years beginning in 1990. The association between diabetes and incidence of dementia/CIND was examined with competing risk regression models in the SALSA cohort and the association between diabetes and cognitive decline was examined with joint longitudinal-survival models in the SALSA and ARIC cohorts. In the SALSA cohort, Mexican Americans with treated and untreated diabetes had an increased risk of dementia/CIND compared to those without diabetes (HR=2.05, 95% CI: 1.41-2.97 and HR=1.55, 95% CI: 0.93-2.58) after accounting for the competing risk of death. Additionally, Mexican Americans with diabetes experienced modestly accelerated cognitive decline compared to those without diabetes. In the ARIC cohort, earlier onset of diabetes was associated with greater cognitive decline in mid-life among African Americans. No association between diabetes and cognitive decline was observed among whites. These findings provide evidence that the association between diabetes and dementia/CIND among Mexican Americans remains strong after accounting for the competing risk of mortality. The association between diabetes and cognitive decline is less evident. Future research is needed to identify how diabetes treatments influence cognitive decline among people with diabetes